Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [4].
Biosimilar drugs: In 2016 biosimilar agent CT-P13 (developed by Celltrion, also known as infliximab-dyyb; Remsima®, Inflectra®) was approved in several countries for use in all indications for which reference infliximab is approved [1-2,7]. Although the approval covers the same indicated conditions as the reference drug, it should be noted that CT-P13 is approved as a biosimilar and not as an interchangeable product. Flixabi® (a.k.a. Renflexis®, SB2, infliximab-abda), another infliximab biosimilar (manufactured and commercialized by Biogen in the EU) received EMA marketing authorisation in 2016, followed by FDA approval in April 2017. PF-06438179 is another potential biosimilar to infliximab being developed by Pfizer Inc. [3]. |
